Testing a new drug combination for hard-to-treat lymphoma

This study is testing a new treatment approach for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has either come back or stopped responding to standard chemotherapy. The trial combines a medication called decitabine with an existing chemotherapy regimen called COP. Researchers believe that decitabine may help wake up cancer-fighting genes in your body and make the existing chemotherapy work better.

Many patients with DLBCL find that standard treatments stop working over time, and there is a real need for better options. This medication works differently than traditional chemotherapy — it targets how cancer cells control their genes — and early research suggests it may help improve how well treatment works and how long patients survive.